MSD
Contact UsWorldwide
   
Home Products Research About MSD
Invanz
Online Material
E-mail updates
לתמיכה טכנית




INVANZ® HAS DEMONSTRATED EXCELLENT CLINICAL EFFICACY
IN THE TREATMENT OF INTRA-ABDOMINAL INFECTIONS:*

In a randomized, double-blind clinical study with piperacillin-tazobactam,1 INVANZ showed:

  • A response rate** of over 90% at the end of IV therapy1
  • A response rate** of  87% four to six weeks post-therapy1
  • Consistently high response rates* across a variety of infectious sites1
  • Consistently high response rates* across a variety of infectious processes1
  • Efficacy comparable to that of piperacillin-tazobactam1
    Study Details

In a randomized, double-blind clinical study with ceftriaxone plus metronidazole,2 INVANZ showed:

  • A response rate* of 90% at the end of IV therapy2
  • A response rate* of 84% four to six weeks post-therapy2
  • Efficacy comparable to that of ceftriaxone plus metronidazole2
    Study Details
RELATED ARTICLE

Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Annals of Surgery.
View Article
 
  *Intra-abdominal infections requiring surgical intervention
**Response was defined as a favorable clinical and microbiologic response.1,2
View referencesView References PrintPrintable Version

MSD- Merck Sharp & Dohme, Israel